Patents represent a crucial milestone in translating fundamental peptide research into tangible therapeutic solutions. Within the framework of this project, intellectual property protection safeguards novel discoveries involving peptide-based delivery systems and antibody molecules designed to address complex diseases. These patent filings reflect years of collaborative effort among researchers across multiple sectors and countries, ensuring that innovative approaches against cancer and pathogenic bacteria can progress toward clinical development. By securing these inventions, the consortium creates a foundation for future biopharmaceutical applications, enabling promising molecular candidates to move from laboratory proof of concept toward regulated drug development pathways.

The patent landscape covered by this initiative spans several therapeutic frontiers, including antimicrobial and antitumoural applications. Novel chimeric molecules that combine targeting domains with bioactive peptides represent a particularly active area of intellectual property generation. These hybrid constructs are designed to overcome biological barriers that traditionally limit peptide drug delivery. Patent protection for such technologies is essential for attracting future investment and establishing partnerships with pharmaceutical industry stakeholders. The strategic filing of patents ensures that discoveries made through staff exchanges and collaborative research remain protected while the consortium pursues downstream validation and commercialisation opportunities.

Each patent application emerging from this project builds upon rigorous preclinical evidence and mechanistic understanding of peptide interactions with disease targets. The process of patenting requires careful documentation of experimental data, claims definition, and legal review across multiple jurisdictions. For peptide-based innovations, claims often focus on specific amino acid sequences, delivery formulations, and methods of therapeutic use. This intellectual property strategy aligns with the project's broader mission to advance biopharmaceutical drug development from academic discovery toward market-ready products. Patents thus serve both as a measure of scientific output and as a gateway to real-world patient impact.

Beyond legal protection, patents function as knowledge dissemination tools that enrich the wider scientific community. Published patent applications disclose technical details that can inspire further research and collaboration across disciplines. For early-career researchers involved in this Marie Skłodowska-Curie action, contributing to a patent filing provides invaluable experience in translating bench science into protectable assets. This training component strengthens the innovation ecosystem by equipping the next generation of scientists with skills in intellectual property management. Ultimately, the patent portfolio generated by this consortium reinforces the project's commitment to delivering peptide-based therapeutics that address unmet medical needs in oncology and infectious disease.